A new drug to treat diabetic kidney disease? Taubman Scholar Dr. Frank Brosius partners in clincial trial
With almost 2 million new cases diagnosed each year, more than 8% of the U.S. population has diabetes. And roughly 30% will eventually develop diabetic kidney disease.
Researchers at the University of Michigan Medical School are partnering with Eli Lilly and Company in using a human genome-wide data set, together with mouse models, to identify a key driver of diabetic kidney disease.
Sponsored by Lilly, a new clinical study will examine whether a drug being developed to treat arthritis and skin diseases can be repurposed to help prevent progression of diabetic kidney disease. It takes advantage of genome-wide expression data analyzed by Matthias Kretzler, M.D., Frank Brosius, M.D. and their teams, as well as the investigators’ expertise in animal models of diabetic complications.
"We prioritized this pathway as the most relevant in diabetic nephropathy," said Kretzler. "Together with data from model systems published, there was such strong evidence that Lilly repurposed their compound and started a phase II trial in less than 15 months. It’s exciting because this kind of collaboration between industry and academia is exactly the way we can accelerate new therapies to help patients."
Kretzler is widely recognized for international multicenter studies of genome-wide expression profiles of major diseases affecting human kidneys including diabetes, hypertension and autoimmune diseases like lupus.
"Dr. Kretzler put together a network of research teams to establish a worldwide human genome-wide renal gene expression consortium,” noted Brosius, whose lab is one of 12 organizations participating in the NIH-sponsored Animal Models of Diabetic Complications Consortium. "Then my group provided the animal model studies and the in-depth understanding of diabetic complications that allowed us to focus on the pathway. This highly collaborative approach makes the U-M one of the only places in the world with the combined expertise to move this project forward."
Stem cell symposium set for Sept. 19 in Ann Arbor
Dr. Eva Feldman will be among the speakers at the one-day event, which focuses on cutting-edge developments in stem-cell biology, epigenetics and regneratrive medicine.
Click here for details and registration.
New U-M President visits Taubman Institute
The Institute hosted a fellow clinician-scientist when the University of Michigan’s new president paid a visit to the A. Alfred Taubman Biomedical Science Research Building.
People who care
Institute welcomes new gift officer
Maria Muller has been appointed to work with connect donors with funding opportunities at the Taubman Institute.
Click here to read more.
news & events
Institute symposium set for Oct. 10
The A. Alfred Taubman Medical Research Institute will award the 2014 $100,000 Taubman Prize for Excellence in Translational Medical Science at its 7th annual symposium at 10 a.m. on Oct. 10.
Dr. Carl June, a physician-scientist who developed a personalized immunotherapy for leukemia using patients’ own T cells, will receive the honor and deliver the symposium's keynote address.
Click here for symposium details.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.